financetom
Business
financetom
/
Business
/
Paperboards maker Clearwater Paper's Q3 net loss rises on goodwill impairment charges
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Paperboards maker Clearwater Paper's Q3 net loss rises on goodwill impairment charges
Oct 28, 2025 1:40 PM

Overview

* Clearwater Paper ( CLW ) Q3 revenue grows 1% yr/yr, beating analyst expectations

* Company reports Q3 net loss of $53 mln due to $45 mln goodwill impairment

* Adjusted EBITDA for Q3 falls to $18 mln from $21 mln last year

Outlook

* Clearwater Paper ( CLW ) sees SBS market in oversupply, impacting consumer paperboard market

* Company focuses on reducing fixed costs and maintaining market share

* Clearwater Paper ( CLW ) optimistic about long-term cash flows and returns from high-quality assets

Result Drivers

* SHIPMENT VOLUME - 3% increase in shipment volumes contributed to higher net sales

* GOODWILL IMPAIRMENT - $45 mln non-cash goodwill impairment charge drove net loss

* MAINTENANCE OUTAGE - Major maintenance outage at Lewiston mill cost $24 mln

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $399 mln $389 mln

(1

Analyst)

Q3 EPS -$3.30

Q3 Net -$53 mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the paper products peer group is "buy"

* Wall Street's median 12-month price target for Clearwater Paper Corp ( CLW ) is $33.00, about 41.2% above its October 27 closing price of $19.39

* The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Arca Biopharma Announces 1-For-12 Reverse Stock Split In Connection With The Proposed Merger With Oruka Therapeutics
BRIEF-Arca Biopharma Announces 1-For-12 Reverse Stock Split In Connection With The Proposed Merger With Oruka Therapeutics
Aug 23, 2024
Aug 23 (Reuters) - ARCA Biopharma Inc ( ABIO ): * ARCA BIOPHARMA ANNOUNCES 1-FOR-12 REVERSE STOCK SPLIT IN CONNECTION WITH THE PROPOSED MERGER WITH ORUKA THERAPEUTICS Source text for Eikon: Further company coverage: ...
BRIEF-Proreit Announces Agreement To Acquire Industrial Building In Montréal For $32.6 Million
BRIEF-Proreit Announces Agreement To Acquire Industrial Building In Montréal For $32.6 Million
Aug 23, 2024
Aug 21 (Reuters) - PRO Real Estate Investment Trust : * PROREIT ANNOUNCES AGREEMENT TO ACQUIRE INDUSTRIAL BUILDING IN MONTRÉAL FOR $32.6 MILLION * PRO REAL ESTATE INVESTMENT TRUST: PURCHASE PRICE TO BE FINANCED THROUGH NEW $21.2 MILLION FIVE-YEAR FIRST MORTGAGE AT RATE OF 5.10% Source text for Eikon: Further company coverage: ...
Novonor unit settles $30.76 million for contract incompliance with Panama City airport
Novonor unit settles $30.76 million for contract incompliance with Panama City airport
Aug 23, 2024
PANAMA CITY, Aug 23 (Reuters) - Panama's Tocumen International Airport said on Friday that a construction firm controlled by Brazil's Novonor had been ordered to pay some $30.76 million to the airport for failure to comply with a contract to expand one of its terminals. The firm now known as CNO, S.A. was granted a contract to expand Tocumen's Terminal...
Biogen, Eisai's Mild Dementia Treatment Gets Marketing Authorization From UK Regulatory Authority
Biogen, Eisai's Mild Dementia Treatment Gets Marketing Authorization From UK Regulatory Authority
Aug 23, 2024
06:31 AM EDT, 08/22/2024 (MT Newswires) -- Biogen (BIIB) and Japan's Eisai Co. ( ESALF ) said early Thursday that their humanized amyloid-beta monoclonal antibody, lecanemab, received marketing authorization from the UK's regulatory authority. The company said lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in certain types of adult patients....
Copyright 2023-2026 - www.financetom.com All Rights Reserved